Abstract
Targeting angiogenesis, the formation of blood vessels, is an important modality for cancer therapy. TNP-470, a fumagillin analog, is among the most potent and broad-spectrum angiogenesis inhibitors. However, a major clinical limitation is its poor oral availability and short half-life, necessitating frequent, continuous parenteral administration. We have addressed these issues and report an oral formulation of TNP-470, named Lodamin. TNP-470 was conjugated to monomethoxy-polyethylene glycol–polylactic acid to form nanopolymeric micelles. This conjugate can be absorbed by the intestine and selectively accumulates in tumors. Lodamin significantly inhibits tumor growth, without causing neurological impairment in tumor-bearing mice. Using the oral route of administration, it first reaches the liver, making it especially efficient in preventing the development of liver metastasis in mice. We show that Lodamin is an oral nontoxic antiangiogenic drug that can be chronically administered for cancer therapy or metastasis prevention.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Holmgren, L., O'Reilly, M. & Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1, 149–153 (1995).
Naumov, G. & Folkman, J. Strategies to prolong the nonangiogenic dormant state of human cancer. in Antiangiogenic cancer therapy Edn. 1. (ed. Darren, W., Herbst, R.S., Abbruzzese, J.L.) 3–23 (CRS Press, Boca Raton, FL, Taylor and Francis, 2007).
Ingber, D. et al. Synthetic analogue of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348, 555–557 (1990).
Folkman, J. & Kalluri, R. Tumor angiogenesis. in Cancer Medicine Vol. 1. (ed. Kufe, D. et al.) 161–194 (B.C. Decker Inc., Hamilton, Ontario, 2003).
Yamaoka, M., Yamamoto, T., Ikeyama, S., Sudo, K. & Fujita, T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res. 53, 5233–5236 (1993).
Shusterman, S. et al. The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin. Cancer Res. 7, 977–984 (2001).
Yanase, T., Tamura, M., Fujita, K., Kodama, S. & Tanaka, K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res. 53, 2566–2570 (1993).
Takamiya, Y., Brem, H., Ojeifo, J., Mineta, T. & Martuza, R. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 34, 869–875 (1994).
Takamiya, Y., Friedlander, R.M., Brem, H. & Malick, A. Martuza, RL Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470. J. Neurosurg. 78, 470–476 (1993).
Emoto, M., Tachibana, K., Iwasaki, H. & Kawarabayashi, T. Antitumor effect of TNP-470, an angiogenesis inhibitor, combined with ultrasound irradiation for human uterine sarcoma xenografts evaluated using contrast color Doppler ultrasound. Cancer Sci. 98, 929–935 (2007).
Nahari, D. et al. Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer. Mol. Cancer Ther. 6, 1329–1337 (2007).
Kanamori, M., Yasuda, T., Ohmori, K., Nogami, S. & Aoki, M. Genetic analysis of high-metastatic clone of RCT sarcoma in mice, and its growth regression in vivo in response to angiogenesis inhibitor TNP-470. J. Exp. Clin. Cancer Res. 26, 101–107 (2007).
Sin, N. et al. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. USA 94, 6099–6103 (1997).
Zhang, Y., Griffith, E., Sage, J., Jacks, T. & Liu, J. Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc. Natl. Acad. Sci. USA 97, 6427–6432 (2000).
Mauriz, J. et al. Cell-cycle inhibition by TNP-470 in an in vivo model of hepatocarcinoma is mediated by a p53 and p21WAF1/CIP1 mechanism. Transl. Res. 149, 46–53 (2007).
Kruger, E. & Figg, W.D. TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opin. Investig. Drugs 9, 1383–1396 (2000).
Kudelka, A., Verschraegen, C. & Loyer, E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N. Engl. J. Med. 338, 991–992 (1998).
Tran, H. et al. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother. Pharmacol. 54, 308–314 (2004).
Kudelka, A. et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin. Cancer Res. 3, 1501–1505 (1997).
Herbst, R. et al. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J. Clin. Oncol. 20, 4440–4447 (2002).
Stadler, W. et al. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J. Clin. Oncol. 17, 2541–2545 (1999).
Logothetis, C. et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin. Cancer Res. 7, 1198–1203 (2001).
Bhargava, P. et al. A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin. Cancer Res. 5, 1989–1995 (1999).
Satchi-Fainaro, R. et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med. 10, 255–261 (2004).
Cretton-Scott, E., Placidi, L., McClure, H., Anderson, D. & Sommadossi, J. Pharmacokinetics and metabolism of O-(chloroacetyl-carbamoyl) fumagillol (TNP-470, AGM-1470) in rhesus monkeys. Cancer Chemother. Pharmacol. 38, 117–122 (1996).
Kataoka, K., Harada, A. & Nagasaki, Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 47, 113–131 (2001).
Harris, J. & Chess, R. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2, 214–221 (2003).
Edlund, U. & Albertsson, A. Degradable polymer microspheres for controlled drug delivery. Adv. Polym. Sci. 157, 67–112 (2001).
Rogers, M., Birsner, A. & D'Amato, R. The mouse cornea micropocket angiogenesis assay. Nat. Protoc. 2, 2545–2550 (2007).
Carter, R., Morton, A. & Dunnett, S. Motor coordination and balance in rodents. in Current Protocols in Neuroscience Vol. 8.12. (ed. Taylor G.), 1–8 (John Wiley & Sons, Inc, New York, 2001).
Almog, N. et al. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J. 20, 947–949 (2006).
Marler, J. et al. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics 116, 38–45 (2005).
Folkman, J. & Klement, G. Platelet biomarkers for the detection of disease. US and International Patent 20060204951 (2006).
Cervi, D. et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood (2007).
Kwon, Y. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists. (Plenum, New York, 2001).
Pierri, E. & Avgoustakis, K. Poly(lactide)-poly(ethylene glycol) micelles as a carrier for griseofulvin. J. Biomed. Mater. Res. A 75, 639–647 (2005).
Kakizawa, Y. & Kataoka, K. Block copolymer micelles for delivery of gene and related compounds. Adv. Drug Deliv. Rev. 54, 203–222 (2002).
Torchilin, V. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell. Mol. Life Sci. 61, 2549–2559 (2004).
Nishiyama, N. & Kataoka, K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol. Ther. 112, 630–648 (2006).
Barbera-Guillem, E., Smith, I. & Weiss, L. Cancer-cell traffic in the liver. I. Growth kinetics of cancer cells after portal-vein delivery. Int. J. Cancer 52, 974–977 (1992).
Greish, K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target. 15, 457–464 (2007).
Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6, 688–701 (2006).
Acknowledgements
We thank Donald Ingber for his support and encouragement of this work, Daniela Prox and Jenny Mu for their assistance with animal studies and chemical analysis, Kristin Johnson for the graphic work, Chun Wang (University of Minnesota) for fruitful discussions. We thank D. Figg, National Cancer Institute, for TNP-470. This work is supported in part by a Department of Defense Congressional Award W81XWH-05-1-0115 (to J.F.). The submission of this paper was completed before Folkman passed away in January and is dedicated to him for his support and mentorship.
Author information
Authors and Affiliations
Contributions
O.B. designed and developed Lodamin formulation, designed experiments, performed tissue culture, in vivo studies and histology, analyzed data and wrote the manuscript; O.F. conducted intrasplenic injections, assisted with editing the manuscript; A.A. and I.A. assisted with cell assays and histology; F.C. conducted TEM imaging and analysis; L.B. assisted with animal studies and conducted corneal assays; E.P. performed confocal microscope imaging; Y.N. performed liver toxicity assays; S.K. and G.C. designed, conducted and analyzed neurotoxicity tests in mice; R.J.D. advised, edited the revisited manuscript and supervised corneal assays. J.F. supervised the entire study, designed experiments, analyzed data and edited the manuscript.
Corresponding author
Ethics declarations
Competing interests
We have filed a patent (on June, 2007, Benny, O., Folkman, J., “Fumagillol derivative polymersomes for oral administration,” Children’s Hospital Boston (CHB)). As per CHB policy, the patent application has been assigned to CHB, and CHB is responsible for the optioning and licensing of the patent application. Lodamin is under option for licensing to a company for development as a pharmaceutical drug.
Rights and permissions
About this article
Cite this article
Benny, O., Fainaru, O., Adini, A. et al. An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat Biotechnol 26, 799–807 (2008). https://doi.org/10.1038/nbt1415
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1415
This article is cited by
-
Newly synthesized methionine aminopeptidase 2 inhibitor hinders tumor growth
Drug Delivery and Translational Research (2023)
-
Biodegradable nanoparticles combining cancer cell targeting and anti-angiogenic activity for synergistic chemotherapy in epithelial cancer
Drug Delivery and Translational Research (2022)
-
Anticancer natural products from Aspergillus neoniger, an endophyte of Ficus carica
Bulletin of the National Research Centre (2021)
-
RETRACTED ARTICLE: Pharmacokinetics, Biodistribution, and Anti-Angiogenesis Efficacy of Diamino Propane Tetraiodothyroacetic Acid-conjugated Biodegradable Polymeric Nanoparticle
Scientific Reports (2019)
-
Polymer–drug conjugate therapeutics: advances, insights and prospects
Nature Reviews Drug Discovery (2019)